# Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

> **NCT06974344** · PHASE4 · NOT_YET_RECRUITING · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 80 (estimated)

## Conditions studied

- Small-for-Size Syndrome

## Interventions

- **DRUG:** Octreotide (drug)
- **PROCEDURE:** Splenic Artery Ligation (SAL)

## Key facts

- **NCT ID:** NCT06974344
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2030-05-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06974344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06974344, "Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06974344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*